awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q47103417-09BAEF06-224D-462E-A8C3-A755DF96C932
Q47103417-09BAEF06-224D-462E-A8C3-A755DF96C932
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47103417-09BAEF06-224D-462E-A8C3-A755DF96C932
Dose/Exposure-Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis.
P2860
Q47103417-09BAEF06-224D-462E-A8C3-A755DF96C932
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47103417-09BAEF06-224D-462E-A8C3-A755DF96C932
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
6e74972c72cce51ff09c84f27136f84befcbcf24
P2860
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.